Trial Profile
REstore physiological Sleep with The Orexin Receptor antagonist Almorexant
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Almorexant (Primary)
- Indications Insomnia
- Focus Therapeutic Use
- Acronyms RESTORA
- 28 Jan 2011 Status changed from planning to discontinued, according to a GlaxoSmithKline and Acetelion joint media release.
- 24 Dec 2009 New trial record